Finepoint Capital LP
- SEC CIK
- 0001608126
- Latest filing
- Aug 13, 2026
Holdings in Q4 2024
Holdings as of Dec 31, 2024, filed Feb 13, 2025. Long positions only; changes compare share counts with Q3 2024.
- Positions
- 24
- 0 vs. Q3 2024
- Portfolio value
- $866.9M
- +$44.5M (+5.4%) vs. Q3 2024
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| QXOQXO, Inc. | COM NEW | 24,933,825 | $396.4M | 45.7% | −816,956−3.2% | Reduced | History |
| LBRDKLiberty Broadband Corp | COM SER C | 2,015,710 | $150.7M | 17.4% | +21,200+1.1% | Added | History |
| LLYVKLiberty Live Holdings, Inc. | COM LBTY LIV S C | 812,792 | $55.3M | 6.4% | +812,792 | New | History |
| ARGXArgenx SE | SPONSORED ADR | 52,928 | $32.6M | 3.8% | −1,500−2.8% | Reduced | History |
| RVMDRevolution Medicines, Inc. | COM | 710,260 | $31.1M | 3.6% | −21,700−3.0% | Reduced | History |
| SWTXSpringWorks Therapeutics, Inc. | COM | 748,752 | $27.1M | 3.1% | +97,900+15.0% | Added | History |
| ASNDAscendis Pharma A/S | SPONSORED ADR | 184,872 | $25.5M | 2.9% | −5,200−2.7% | Reduced | History |
| MLTXMoonLake Immunotherapeutics | CLASS A ORD | 447,935 | $24.3M | 2.8% | +59,100+15.2% | Added | History |
| SRPTSarepta Therapeutics, Inc. | COM | 161,935 | $19.7M | 2.3% | +28,400+21.3% | Added | History |
| LKFTLakefront Biotherapeutics NV | SPON ADR | 674,762 | $18.6M | 2.1% | +117,000+21.0% | Added | History |
| XNCRXencor Inc | COM | 660,000 | $15.2M | 1.7% | +660,000 | New | History |
| CYTKCytokinetics Inc | COM NEW | 318,448 | $15.0M | 1.7% | +61,999+24.2% | Added | History |
| ARVNArvinas, Inc. | COM | 713,778 | $13.7M | 1.6% | +139,400+24.3% | Added | History |
| Avidity Biosciences, Inc.05370A108 | COM | 391,300 | $11.4M | 1.3% | +391,300 | New | – |
| PRTAProthena Corp Public Ltd Co | SHS | 657,071 | $9.10M | 1.0% | +223,600+51.6% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 2,175,646 | $8.96M | 1.0% | +549,500+33.8% | Added | History |
| EYPTEyePoint, Inc. | COM NEW | 1,111,104 | $8.28M | 1.0% | +403,700+57.1% | Added | History |
| SLDBSolid Biosciences Inc. | COM NEW | 961,251 | $3.85M | 0.4% | 00.0% | Unchanged | History |
| ANNAAleAnna, Inc. | COM CL A | 27,717 | $196.8K | <0.1% | +27,717 | New | History |
| ANNAWAleAnna, Inc. | *W EXP 12/13/202 | 490,000 | $68.6K | <0.1% | +490,000 | New | History |
| MNYWWMoneyHero Ltd | *W EXP 09/13/202 | 895,000 | $49.4K | <0.1% | 00.0% | Unchanged | History |
| Ys Biopharma Co LtdG9845F117 | *W EXP 03/15/202 | 489,999 | $48.5K | <0.1% | 00.0% | Unchanged | – |
| Marblegate Acquisition Corp.56608A113 | *W EXP 08/31/202 | 735,000 | $25.7K | <0.1% | 00.0% | Unchanged | – |
| CLDICalidi Biotherapeutics, Inc. | COM | 12,500 | $14.4K | <0.1% | 00.0% | Unchanged | History |
Options (2)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| SPYSPDR S&P 500 ETF Trust | ETF | $442.5M | – |
| iShares Russell 2000 ETF464287655 | ETF | $328.1M | – |
Sold out since Q3 2024 (5)
Positions held at the end of Q3 2024 that are gone from this filing.
| Security | Class | Shares in Q3 2024 | Value in Q3 2024 | % of portfolio in Q3 2024 | History |
|---|---|---|---|---|---|
| TVTXTravere Therapeutics, Inc. | COM | 1,782,267 | $24.9M | 3.0% | History |
| ACADAcadia Pharmaceuticals Inc | COM | 905,384 | $13.9M | 1.7% | History |
| Swiftmerge Acquisition CorpG63836111 | *W EXP 12/13/202 | 490,000 | $39.2K | <0.1% | – |
| Compass Digital Acquisitn CoG2476C123 | *W EXP 09/29/202 | 459,906 | $28.1K | <0.1% | – |
| CLDWWCalidi Biotherapeutics, Inc. | *W EXP 03/14/202 | 655,200 | $8.58K | <0.1% | History |